Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review
GLP-1 drugs, already used for diabetes, show early promise in protecting against substance use disorders based on current safety and observational evidence.
BACKGROUND/OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have an exciting future potential beyond metabolic disorders. CONCLUSION: GLP-1RAs have good potential protective properties against SUD especially in observational research with good safety.
What the study was
- Study design
- Systematic Review
- Population
- BACKGROUND/OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have an exciting future p
- Category
- Prevention
- Maturity
- Validated
- Journal
- Disease-a-month : DM
Why it surfaced
High-level evidence synthesis; moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.